Physician profile

Maria Read

Nurse Practitioner · Charles Town, WV

NPI 1588877609

$689.19

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$12.76

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $222.16 2021-2022
Medtronic, INC. $162.75 2022-2023 Intellis Adaptivestim
Collegium Pharmaceutical, INC. $130.81 2021-2022
Ibsa Pharma INC. $59.91 2021-2022
Nevro Corp. $34.48 2021
Redhill Biopharma INC. $18.82 2021
Stimwave Technologies Incorporated $15.89 2021
Biodelivery Sciences International, INC. $15.78 2021
Scilex Pharmaceuticals INC. $14.57 2021
Grt US Holding, INC. $14.02 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Maria Read

$689.19

in general payments reported 2019-2025

Years
2021-2023
Top company
Abbott Laboratories

https://glasscript.com/doctor/10762076/maria-read

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.